Vir Biotechnology Inc (VIR) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally.

Total Cash From Operating Activities Chart for Vir Biotechnology Inc

Vir Biotechnology Inc (VIR) operating cash flow for FY2025 was USD -391.8M. Vir Biotechnology Inc's operating cash flow moved from USD -66.4M in 2017 to USD -391.8M in 2025 over 8 years.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$1.79B
Implied Share Price
$10.57
Enterprise Value
$282.48M
Revenue (TTM)
$303.23M
EBITDA
-$267.96M
Profit Margin
-83.00%
Trailing P/E
—
Forward P/E
4.27
Price/Book (MRQ)
0.83
Price/Sales (TTM)
5.90
EV/EBITDA
0.90
EV/Revenue
19.63
Dividend Yield
—
Book Value
$5.81
Free Cash Flow (FY2025)
-$396.61M
Free Cash Flow Yield
-22.17%

Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.